Navigation Links
Todd Rider Joins Draper to Continue Antiviral Therapeutics Development

Cambridge, MA (PRWEB) January 08, 2014

Todd Rider has joined Draper Laboratory to continue his work on treatments that are effective against a wide array of pathogens, rather than specific threats.

Rider received his Ph.D. from MIT in 1995 and served as a senior staff scientist at MIT Lincoln Laboratory until October 2013. While at Lincoln Laboratory, Rider began development of a broad-spectrum antiviral therapeutic drug called DRACO, which TIME Magazine hailed as one of the top inventions of the year 2011, and the White House described as “visionary” in its 2012 National Biotechnology Blueprint.

Upon administration to an animal or hopefully someday a person, Rider’s DRACO drug rapidly identifies virus-infected cells and eliminates them while leaving healthy cells untouched, thus eliminating the infection. DRACO, which stands for Double-stranded RNA Activated Caspase Oligomerizer, has proven effective and nontoxic in mice and in 11 different human and animal cell types against 15 different viruses, ranging from the common cold to dengue hemorrhagic fever.

Rider is expanding his DRACO research at Draper and is testing against strains of various other viruses in cells and animals; the team looks forward to larger scale animal trials and clinical human trials within a decade or less. DRACO is part of Rider’s PANACEA project, a family of broad-spectrum therapeutics that he invented.

Rider holds a joint appointment with MIT’s Edgerton Center, where he is also working to develop innovative programs to improve K-12 science education, drawing on his extensive previous experience creating and running educational outreach programs at Lincoln Laboratory.

Draper Laboratory

Draper Laboratory, which celebrates 80 years of service to the nation in 2013, is a not-for-profit, engineering research and development organization dedicated to solving critical national problems in national security, space systems, biomedical systems, and energy. Core capabilities include guidance, navigation and control, miniature low power systems, highly reliable complex systems, information and decision systems, autonomous systems, biomedical and chemical systems, and secure networks and communications.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. "Just Label It" condemns dangerous riders snuck into the Farm Bill by chemical companies working to keep Americans in the dark about their food
2. Jesper Bramming, former A.P. Moller Executive, Joins the CMC Biologics Executive Management Team as Chief Financial Officer
3. Dr. Daniel Von Hoff Joins Lixte Biotechnologys Scientific Advisory Board
4. Bioentrepreneurship Leader Joins UM Ventures Team
5. Anthony A. Charity Joins Tunnell Consulting
6. CHI Joins More Than 30 State Life Sciences Associations in Urging Budget Conferees to Fix FDA User Fee Sequester
7. Craig Peloquin Joins Glissandra Skin Care as VP of Sales and Marketing
8. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
9. Dr. Ungerleider Joins Forces with Childhelp
10. ReachMD Radio Joins Clear Channel’s iHeartRadio
11. Soltex Consulting Joins Medidata Partner Program to Better Optimize Clinical Processes
Post Your Comments:
(Date:11/25/2015)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... discussion at the Piper Jaffray 27th Annual Healthcare Conference ... is scheduled for Wednesday, December 2, at 8:00 a.m. ... will be available for 14 days after the event.  ... Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... ... 24, 2015 , ... International Society for Pharmaceutical Engineering (ISPE) ... annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in ... largest number of attendees in more than a decade. , “The 2015 ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):